Advertisement
Singapore markets open in 1 hour 29 minutes
  • Straits Times Index

    3,187.66
    +32.97 (+1.05%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • Dow

    37,775.38
    +22.07 (+0.06%)
     
  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     
  • Bitcoin USD

    63,519.80
    +2,243.81 (+3.66%)
     
  • CMC Crypto 200

    1,314.91
    +429.37 (+48.51%)
     
  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     
  • Gold

    2,395.20
    -2.80 (-0.12%)
     
  • Crude Oil

    82.56
    -0.17 (-0.21%)
     
  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     
  • Nikkei

    38,079.70
    +117.90 (+0.31%)
     
  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     
  • FTSE Bursa Malaysia

    1,544.76
    +4.34 (+0.28%)
     
  • Jakarta Composite Index

    7,166.81
    -7,130.84 (-49.87%)
     
  • PSE Index

    6,523.19
    +73.15 (+1.13%)
     

Genetic Signatures' (ASX:GSS) investors will be pleased with their splendid 159% return over the last five years

It hasn't been the best quarter for Genetic Signatures Limited (ASX:GSS) shareholders, since the share price has fallen 22% in that time. But that doesn't change the fact that shareholders have received really good returns over the last five years. We think most investors would be happy with the 159% return, over that period. We think it's more important to dwell on the long term returns than the short term returns. The more important question is whether the stock is too cheap or too expensive today.

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.

Check out our latest analysis for Genetic Signatures

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

ADVERTISEMENT

During the last half decade, Genetic Signatures became profitable. That kind of transition can be an inflection point that justifies a strong share price gain, just as we have seen here.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

earnings-per-share-growth
earnings-per-share-growth

It is of course excellent to see how Genetic Signatures has grown profits over the years, but the future is more important for shareholders. Take a more thorough look at Genetic Signatures' financial health with this free report on its balance sheet.

A Different Perspective

While the broader market lost about 2.5% in the twelve months, Genetic Signatures shareholders did even worse, losing 22%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 21% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Genetic Signatures (at least 1 which is a bit concerning) , and understanding them should be part of your investment process.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on AU exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here